What’s Moving These Hot Stocks: Vertex Pharmaceuticals, BroadSoft, PetMed, Cognizant Technology
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) says that an interim evaluation of data from an ongoing Phase 2 study of VX-809 and KALYDECO, showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del. The analysis was conducted after approximately half of the study patients had completed 56 days of treatment. Monday’s results are based on data from 37 homozygous F508del patients who completed treatment in the 56-day study and 11 patients with one or two copies of the F508del mutation who received a placebo. Improvement in lung function was statistically significant across the combined treatment groups relative to baseline compared to placebo. Of those who received VX-809 and KALYDECO, approximately 46 percent experienced an absolute improvement from baseline to Day 56 in lung function of 5 percentage points or more, with approximately 30 percent experiencing an absolute improvement from baseline to Day 56 of 10 percentage points or more.
Don’t Miss: Is Apple Waving the White Flag in China?
BroadSoft, Inc. (NASDAQ:BSFT) posts first quarter revenue of $38.3 million vs. consensus of $36.97 million.
PetMed Express Inc. (NASDAQ:PETS) reports fourth quarter revenue of $55.9 million against estimates of %52.05 million.
Cognizant Technology Solutions Corp. (NASDAQ:CTSH): India-based information tech suppliers in India far outstripped their peers worlwide, says Gartner, Inc., according to an Economic Times report. Indian providers grew at 23.8 percent in 2011, compared with 7.7 percent for the firms outside that country. Cognizant topped Wipro to become third there, with its growth of 33.3 percent, which was the highest of the top five, which also include TCS, Infosys (NASDAQ:INFY) and HCL Technologies.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
Investing Insights: The Week Ahead on Wall Street: Earnings Hits Last Lap, Consumer Credit on Tap.